Literature DB >> 22833492

Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus.

Farruk M Lutful Kabir1, Payal Agarwal, Patricia Deinnocentes, Jishan Zaman, Allison Church Bird, R Curtis Bird.   

Abstract

The INK4 family of cyclin-dependent kinase inhibitors (CKI) encode important cell cycle regulators that tightly control cell cycle during G1 to S phase. These related genes are considered tumor suppressors as loss of function contributes to the malignant phenotype. Expression of CKIs p16, p14ARF, or p15 were defective in six different canine mammary tumor (CMT) cell lines compared to normal thoracic canine fibroblasts. This suggests CKI defects are frequently responsible for neoplastic transformation in canine mammary carcinomas. p16 and p14ARF are two alternatively spliced products derived from the canine p16/INK4A/p14ARF gene locus. Despite omissions in the published p16 transcript and canine genome and the presence of GC-rich repeats, we determined the complete coding sequence of canine p16 revealing a deletion and frameshift mutation in p16 exon 1α in CMT28 cells. In addition, we determined canine p14ARF mRNA and protein sequences. Mapping of these mutations uncovered important aspects of p16 and p14ARF expression and defects in CMT28 cells shifting the p16 reading frame into p14ARF making a fusion protein that was predicted to be truncated, unstable and devoid of structural and functional integrity. This data describes an important neoplastic mechanism in the p16/INK4A/p14ARF locus in a spontaneous canine model of breast cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22833492     DOI: 10.1002/jcb.24300

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

2.  In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.

Authors:  Samantha Guillemette; Charlène Rico; Philippe Godin; Derek Boerboom; Marilène Paquet
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-08-18       Impact factor: 2.673

3.  Evaluation of 14-3-3 sigma as a potential partner of p16 in quiescence and differentiation.

Authors:  Payal Agarwal; Patricia DeInnocentes; R Curtis Bird
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-08-30       Impact factor: 2.416

4.  Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.

Authors:  Farruk M Lutful Kabir; Patricia DeInnocentes; Allison Church Bird; R Curtis Bird
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-05-20       Impact factor: 2.416

Review 5.  Genetic Pathways of Aging and Their Relevance in the Dog as a Natural Model of Human Aging.

Authors:  Sára Sándor; Enikő Kubinyi
Journal:  Front Genet       Date:  2019-10-18       Impact factor: 4.599

Review 6.  Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression.

Authors:  Farruk M Lutful Kabir; Carlos E Alvarez; R Curtis Bird
Journal:  Vet Sci       Date:  2015-12-25

7.  Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer.

Authors:  Farruk M Lutful Kabir; Patricia DeInnocentes; Payal Agarwal; Christopher P Mill; David J Riese Nd; R Curtis Bird
Journal:  J Vet Sci       Date:  2017-06-30       Impact factor: 1.672

8.  Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma.

Authors:  R Curtis Bird; Patricia DeInnocentes; Allison E Church Bird; Farruk M Lutful Kabir; E Gisela Martinez-Romero; Annette N Smith; Bruce F Smith
Journal:  J Vet Sci       Date:  2019-09       Impact factor: 1.672

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.